
Maxim analyst Naz Rahman downgraded Aytu BioPharma (AYTU) to Hold from Buy after the company agreed to be acquired by Rosemont Pharmaceuticals for $2.70 per share in cash. Published first
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| AYTU | Aytu BioScience | 2.66 | 0.65 | 32.34% |
| Name | Price | % Change | |
|---|---|---|---|
| $2.66 | +32.34% |

Maxim analyst Naz Rahman downgraded Aytu BioPharma (AYTU) to Hold from Buy after the company agreed to be acquired by Rosemont Pharmaceuticals for $2.70 per share in cash. Published first

Lake Street downgraded Aytu BioPharma (AYTU) to Hold from Buy with a price target of $2.70, down from $7, after the company agreed to be acquired by Rosemont Pharmaceuticals for

Aytu BioScience ( ($AYTU) ) just unveiled an update. On November 16, 2026, Aytu BioPharma entered an agreement with Rosemont Pharmaceuticals Holdings for Rosemont to acquire the company through a

Reports Q1 revenue $14.84M, consensus $13.27M. “Our first quarter performance was driven by growth in EXXUA, with net revenue increasing to $4.9 million and total prescriptions growing to 4,400 for

16:40 EST AYTU BioPharma (AYTU) trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders’ Hot Stocks on TipRanks >>

Aytu BioPharma (AYTU) announced that it has entered into a definitive merger agreement with Rosemont Pharmaceuticals, pursuant to which Rosemont would acquire Aytu, through a tender offer for $2.70 per

16:00 EST AYTU BioPharma (AYTU) trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s best-performing stocks on

Aytu BioScience (AYTU) is scheduled to report 1st quarter earnings on 11/16/2026, after the market closes. Regarding Q1 estimates, Wall Street analysts expect Aytu BioScience to post earnings of -$0.26

Aytu BioScience (($AYTU)) has held its Q4 earnings call. Read on for the main highlights of the call. Aytu BioScience struck an upbeat tone in its latest earnings call, emphasizing

Reports Q4 revenue $16.1M, consensus $12.28M. “Although we remain in the early stages of the EXXUA launch, the continued momentum we saw throughout the fourth quarter further reinforces our confidence
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Feb 17, 2027TBA | $28.91M | $-0.15 | $15.28M | 0.04 | -1.49 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.